352 related articles for article (PubMed ID: 26271831)
1. Chitosan-based mucosal adjuvants: Sunrise on the ocean.
Xia Y; Fan Q; Hao D; Wu J; Ma G; Su Z
Vaccine; 2015 Nov; 33(44):5997-6010. PubMed ID: 26271831
[TBL] [Abstract][Full Text] [Related]
2. Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.
Smith A; Perelman M; Hinchcliffe M
Hum Vaccin Immunother; 2014; 10(3):797-807. PubMed ID: 24346613
[TBL] [Abstract][Full Text] [Related]
3. Chitosan-based systems for the delivery of vaccine antigens.
Arca HC; Günbeyaz M; Senel S
Expert Rev Vaccines; 2009 Jul; 8(7):937-53. PubMed ID: 19538118
[TBL] [Abstract][Full Text] [Related]
4. Modes of Action for Mucosal Vaccine Adjuvants.
Aoshi T
Viral Immunol; 2017; 30(6):463-470. PubMed ID: 28436755
[TBL] [Abstract][Full Text] [Related]
5. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
6. Chitosan-based Nanoparticles in Mucosal Vaccine Delivery.
Mehrabi M; Montazeri H; Mohamadpour Dounighi N; Rashti A; Vakili-Ghartavol R
Arch Razi Inst; 2018 Sep; 73(3):165-176. PubMed ID: 30280836
[TBL] [Abstract][Full Text] [Related]
7. Advances and Potential Applications of Chitosan Nanoparticles as a Delivery Carrier for the Mucosal Immunity of Vaccine.
Li D; Fu D; Kang H; Rong G; Jin Z; Wang X; Zhao K
Curr Drug Deliv; 2017; 14(1):27-35. PubMed ID: 27494157
[TBL] [Abstract][Full Text] [Related]
8. New insights in mucosal vaccine development.
Pavot V; Rochereau N; Genin C; Verrier B; Paul S
Vaccine; 2012 Jan; 30(2):142-54. PubMed ID: 22085556
[TBL] [Abstract][Full Text] [Related]
9. Advances and challenges in mucosal adjuvant technology.
Newsted D; Fallahi F; Golshani A; Azizi A
Vaccine; 2015 May; 33(21):2399-405. PubMed ID: 25865473
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation.
Vasiliev YM
Expert Rev Vaccines; 2015 Jan; 14(1):37-53. PubMed ID: 25262982
[TBL] [Abstract][Full Text] [Related]
11. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
[TBL] [Abstract][Full Text] [Related]
12. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.
Wang X; Meng D
Protein Cell; 2015 Mar; 6(3):170-84. PubMed ID: 25503634
[TBL] [Abstract][Full Text] [Related]
13. Development of enhanced antibody response toward dual delivery of nano-adjuvant adsorbed human Enterovirus-71 vaccine encapsulated carrier.
Saeed MI; Omar AR; Hussein MZ; Elkhidir IM; Sekawi Z
Hum Vaccin Immunother; 2015; 11(10):2414-24. PubMed ID: 26186664
[TBL] [Abstract][Full Text] [Related]
14. Modified chitosan-based nanoadjuvants enhance immunogenicity of protein antigens after mucosal vaccination.
Sinani G; Sessevmez M; Gök MK; Özgümüş S; Alpar HO; Cevher E
Int J Pharm; 2019 Oct; 569():118592. PubMed ID: 31386881
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant synergy: the effects of nasal coadministration of adjuvants.
Moschos SA; Bramwell VW; Somavarapu S; Alpar HO
Immunol Cell Biol; 2004 Dec; 82(6):628-37. PubMed ID: 15550121
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory effect of chitosan and quaternary chitosan: A review of potential vaccine adjuvants.
Li X; Xing R; Xu C; Liu S; Qin Y; Li K; Yu H; Li P
Carbohydr Polym; 2021 Jul; 264():118050. PubMed ID: 33910752
[TBL] [Abstract][Full Text] [Related]
18. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
Lawson LB; Norton EB; Clements JD
Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
[TBL] [Abstract][Full Text] [Related]
19. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
De Magistris MT
Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
[TBL] [Abstract][Full Text] [Related]
20. Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually.
Spinner JL; Oberoi HS; Yorgensen YM; Poirier DS; Burkhart DJ; Plante M; Evans JT
Vaccine; 2015 Oct; 33(43):5845-5853. PubMed ID: 26392012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
